ClinicalTrials.gg
CompletedNCT00246922Updated Jun 10, 2026

Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 71 y) (APTA-2217-07).

A Phase 3 interventional study of Roflumilast in Bronchial Asthma, sponsored by AstraZeneca. Completed at 1 site in Japan. Open to participants aged 20 Years to 71 Years. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Dec 2004, registered Oct 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
20 Years to 71 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing roflumilast in Asthma — none open to participants now, none under way, none of them phase 3. Roflumilast · Asthma.

Enrollment
6th of 10
150 · median 300
Started
2004
with 3 others
Phase 3
5 of 10
none open now
Registered
6th of 10
by date
Lead sponsor
8 of 10
AstraZeneca

Among the 10 studies testing roflumilast in Asthma, this one is the 6th largest by enrollment, is one of 4 that started in 2004, is one of 5 in phase 3, and was the 6th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 10 studies testing roflumilast in Asthma is open now. The open studies under Asthma, anywhere →

About roflumilast

Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 20 Years to 71 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing roflumilast in Asthma as a file.
02

Study summary

The aim of this long-term study is to investigate the effect of roflumilast (APTA-2217) on the long-term safety in patients with asthma, who completed the 24-week evaluation of study APTA-2217-05. Roflumilast will be administered orally once daily. The present study consists of a 28 weeks treatment period, and is the extension of the 24-week study APTA-2217-05 (registered study). The study will provide further long-term safety and efficacy data of roflumilast.

03

Conditions studied

  • Bronchial Asthma

Browse trials for

Keywords

  • Asthma
  • Roflumilast
  • phosphodiesterase 4 inhibitor
04

Who can participate

Ages eligible
20 Years to 71 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main inclusion criteria:

  • Patients with asthma disease
  • Written
  • Patients who completed the 24-week evaluation of study APTA-2217-05

Main exclusion criteria:

  • % .0 \< 60% at both 18 weeks and 24 weeks measurements during APTA-2217-05
  • Patients with poorly controlled asthma between informed consent day and study starting day: need for oral or intravenous therapy, hospitalization or any emergency visit, PEF value worsened for 2 or more consecutive days
  • Serious diseases
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
150 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Long-term safety after 28 weeks treatment of Roflumilast at (total 52 weeks, 24 weeks of study APTA-2217-05 followed by 28 weeks) .

Secondary outcomes

  1. Efficacy.

07

Study locations

1 site
  • Nycomed Japan and Mitsubishi Tanabe Pharma Corporation
    Osaka, Japan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2004 to primary completion in Jan 2007, 25 months.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 25 months is close to that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2005
First posted
Nov 1, 2005
StartActual
Dec 1, 2004
Primary completionActual
Jan 1, 2007
CompletionActual
Oct 1, 2007
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00246922
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 1, 2005
Start date
Dec 1, 2004
Primary completion
Jan 1, 2007
Completion
Oct 1, 2007
Last update
Jun 10, 2026

Study contacts

AstraZeneca AstraZeneca
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roflumilast

Start the discussion